Heffernan CB, et al. - Researchers described the characteristics of hearing losses documented in patients treated with clarithromycin alone for nontuberculous mycobacterial nontuberculous mycobacterium (NTM) lymphadenitis in a pediatric tertiary care center over a 12-year period. A 7% hearing loss rate was seen in this series. Their ability to conclude that clarithromycin was the sole cause of these hearing losses (HL) was tempered by confounding issues, such as 1 patient with a syndrome potentially contributing to HL, and limitations to this study, including retrospective design and loss to follow-up. Nonetheless, for a role in clarithromycin causing HL enough supporting data exist that testing should be considered for patients undergoing long-term clarithromycin treatment.